UK’s ‘Pioneering’ Medicines Repurposing Program Delivers First License
Executive Summary
Now that the first license for a drug has been obtained in partnership with the program, work will begin to ensure other companies that make the product adopt the new licensed indication.
You may also be interested in...
European Opportunities Loom For Value Added Medicines
Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels this month. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.
European Opportunities Loom For Value Added Medicines
Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in early November. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.
Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.